Cargando…

Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells

Somatostatin receptors are a pivotal target for treatment of pancreatic neuroendocrine tumors (pNET), either with somatostatin analogues (SSA) or radiolabeled SSA. The highest affinity target for the most commonly used SSA is the somatostatin receptor type 2 (sst(2)). An important factor that may co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veenstra, Marije J., van Koetsveld, Peter M., Dogan, Fadime, Farrell, William E., Feelders, Richard A., Lamberts, Steven W.J., de Herder, Wouter W., Vitale, Giovanni, Hofland, Leo J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871078/ https://www.ncbi.nlm.nih.gov/pubmed/29599907 http://dx.doi.org/10.18632/oncotarget.9462

Ejemplares similares

Effect of epigenetic treatment on SST(2) expression in neuroendocrine tumour patients
por: Refardt, Julie, et al.
Publicado: (2022)

Reciprocal Interactions between Fibroblast and Pancreatic Neuroendocrine Tumor Cells: Putative Impact of the Tumor Microenvironment
por: Cuny, Thomas, et al.
Publicado: (2022)

Epigenetic regulation of SST(2) expression in small intestinal neuroendocrine tumors
por: Klomp, Maria J., et al.
Publicado: (2023)

Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells
por: Herrera-Martínez, Aura D., et al.
Publicado: (2019)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study
por: Campana, Claudia, et al.
Publicado: (2022)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women
por: Blažević, Anela, et al.
Publicado: (2022)

Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line
por: Bresciani, Giulia, et al.
Publicado: (2019)

Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours
por: Blažević, Anela, et al.
Publicado: (2021)

Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives
por: Herrera-Martínez, Aura D., et al.
Publicado: (2018)

Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells
por: Booy, Stephanie, et al.
Publicado: (2014)

Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
por: Hofland, Johannes, et al.
Publicado: (2020)

Aberrant tryptophan metabolism in stromal cells is associated with mesenteric fibrosis in small intestinal neuroendocrine tumors
por: Blažević, Anela, et al.
Publicado: (2022)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

The Role of the IGF2 Methylation Score in Diagnosing Adrenocortical Tumors with Unclear Malignant Potential—Feasibility of Formalin-Fixed Paraffin-Embedded Tissue
por: Steenaard, Rebecca V., et al.
Publicado: (2023)

Induction therapy with (177)Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients
por: Minczeles, Noémie S., et al.
Publicado: (2022)

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
por: Blaauboer, Amber, et al.
Publicado: (2020)

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
por: Cantone, Maria Celeste, et al.
Publicado: (2021)

FRI296 Somatostatin Receptor 5 Staining In Prolactinomas
por: Mehta, Sonal, et al.
Publicado: (2023)

Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors
por: van Adrichem, R C S, et al.
Publicado: (2013)

Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [(111)In]In-DOTATATE Uptake in NET Cells
por: Klomp, Maria J., et al.
Publicado: (2021)

Epidrugs: Toward Understanding and Treating Diverse Diseases
por: Umehara, Takashi
Publicado: (2022)

Epigenetic Regulation in Breast Cancer: Insights on Epidrugs
por: Kim, Ayoung, et al.
Publicado: (2023)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
por: Zandee, Wouter T, et al.
Publicado: (2021)

Phytochemicals as Potential Epidrugs in Type 2 Diabetes Mellitus
por: Ramírez-Alarcón, Karina, et al.
Publicado: (2021)

The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation
por: Blaauboer, Amber, et al.
Publicado: (2022)

Future treatment strategies of aggressive pituitary tumors
por: Lamberts, Steven W. J., et al.
Publicado: (2008)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Modifying Effects of Glucose and Insulin/Insulin-Like Growth Factors on Colon Cancer Cells
por: Berk, Şeyda, et al.
Publicado: (2021)

ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase
por: Hofland, Johannes, et al.
Publicado: (2013)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy
por: Montalvo-Casimiro, Michel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_beud8lumei9h70vufu0ru65i8v